A study that raised concerns about the purity of generic heart drugs used a faulty methodology that diminishes the credibility of the findings, said Dr. Janet Woodcock, who directs the FDA Center for Drug Evaluation and Research. Woodcock said new research, yet to be published, used a different testing approach and found no contaminants in the drugs tested.

Related Summaries